Hansa Biopharma AB (publ) announced that it has entered into an agreement for a private placement for proceeds of $70 million on July 18, 2022. The transaction included participation from new investor NovaQuest Capital Management, L.L.C. The transaction is expected to close in 15 days.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.74 SEK | +4.72% | +8.86% | +13.51% |
04-18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
04-18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.51% | 152M | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Hansa Biopharma AB announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C.